Effectiveness of probiotics in type 2 diabetes: A meta-analysis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 11, 2015, Pages 803-813

  Kasińska, Marta A ^a   Drzewoski, Józef ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Diabetes; Gut microbiota; Meta analysis; Metabolism; Probiotics

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBIOTIC AGENT; GLUCOSE BLOOD LEVEL;

ARTICLE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; COCHRANE LIBRARY; DATA BASE; DRUG EFFECT; EMBASE; HUMAN; INSULIN RESISTANCE; MEDLINE; META ANALYSIS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SUPPLEMENTATION; TRIACYLGLYCEROL BLOOD LEVEL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH PROMOTION; INTESTINE; LACTOBACILLUS; MALE; MICROBIOLOGY; PROCEDURES; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH PROMOTION; HUMANS; INTESTINES; LACTOBACILLUS; MALE; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84955295921     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.3156     Document Type: Article

References (50)

1. World Health Organization; Food and Agricultural Organization of the United Nations. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Report of a Joint FAO/ WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. 2001. ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf. Accessed February 13, 2015.
2. Floch MH. Recommendations for probiotic use in humans - a 2014 update. Pharmaceuticals (Basel). 2014; 7: 999-1007.
3. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464: 59-65.
4. Ley RE, Bäckhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005; 102: 11070-11075.
5. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444: 1027-1031.
6. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444: 1022-1023.
7. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013; 498: 99-103.
8. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490: 55-60.
9. Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008, 27: 104-119.
10. Schwiertz A, Taras D, Schäfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010; 18: 190-195.
11. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012; 489: 242-249.
12. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr. 2003; 133 (Suppl): 2485S-2493S.
13. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115: 1111-1119.
14. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012; 143: 913-916.
15. Moher D, Liberati A, Tetzlaff J, et al. The PRISMA Group: Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 6: e1000097.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12.
17. Wojciechowski P, Niemczyk-Szechowska P, Olewińska E, et al. Clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. Pol Arch Med Wewn. 2015; 125: 141-151.
18. Brockwell SE, Gordon IR. A comparison of statistical methods for meta-analysis. Statistics in Medicine. 2001; 20: 825-840.
19. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. http://handbook.cochrane.org/. Accessed February 13, 2015.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539-1558.
21. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr. 2010; 104: 1831-1838.
22. Asemi Z, Zare Z, ShakeriH, et al. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab. 2013; 63: 1-9.
23. Asemi Z, Khorrami-Rad A, Alizadeh S, et al. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlledclinical trial. Clin Nutr. 2014; 33: 198-203.
24. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, et al. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012; 28: 539-543.
25. Judiono J, Hadisaputro S, Indranilla KS. Effects of clear kefir on biomolecular aspects of glycemic status of type 2 diabetes mellitus (T2DM) patients in Bandung, West Java [Study on human blood glucose, c peptide and insulin]. The Journal of Functional Foods in Health and Disease. 2014; 4: 340-348.
26. Mahboobi S, Iraj B, Maghsoudi Z, et al. The effects of probiotic supplementation on markers of blood lipids, and blood pressure in patients with prediabetes: a randomized clinical trial. Int J Prev Med. 2014; 5: 1239-1246.
27. Mazloom I, Yousefinejad A, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran J Med Sci. 2013; 38: 38-43.
28. Moroti C, Souza Magri LF, de Rezende Costa M, et al. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012; 11: 29-37.
29. Larsen ML, Hørder M, Mogensen EF. Effect of long-term monitoring of glycosylated haemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med. 1990; 323: 1021-1025.
30. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999; 7: 169-177.
31. Sayin SI, Wahlström A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17: 225-235.
32. Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr. 2012; 66: 1234-1241.
33. Hulston CJ, Churnside AA, Venables MC. Probiotic supplementation prevents high-fat, overfeeding-induced insulin resistance in human subjects. Br J Nutr. 2015; 29: 1-7.
34. Amar J, Chabo C, Waget A, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med. 2011; 3: 559-572.
35. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition. 2007; 23: 62-68.
36. Yadav H, Jain S, Sinha PR. Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. J Dairy Res. 2008; 75: 189-195.
37. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol. 2008; 49: 821-830.
38. Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract. 2010; 2010. pii: 212563. doi: 10.1155/2010/212563
39. Gordon SM, Hofmann S, Askew DS, et al. High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol Metab. 201; 22: 9-15.
40. Xiao JZ, Kondo S, Takahashi N, et al. Effects of Milk Products Fermented by Bifidobacterium longum on Blood Lipids in Rats and Healthy Adult Male Volunteers. J. Dairy Sci. 2003, 86: 2452-2461.
41. Kiessling G, Schneider J, Jahreis, G. Long-Term Consumption of Fermented Dairy Products over 6 Months Increases HDL Cholesterol. Eur J Clin Nutr. 2002; 56: 843-849.
42. Lee SJ, Bose S, Seo JG. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: a randomized double-blind controlled clinical trial. Clin Nutr. 2014; 33: 973-981.
43. Guo Z, Liu XM, Zhang QX, et al. Influence of consumption of probiotics on the plasma lipid profile: A meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis. 2011; 21: 844-885.
44. Agerholm-Larsen L, Bell ML, Grunwald GK, et al. The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. Eur J Clin Nutr. 2000; 54: 856-860.
45. Fink LN, Zeuthen LH, Ferlazzo G. Human antigen-presenting cells respond differently to gut-derived probiotic bacteria but mediate similar strain-dependent NK and T cell activation. FEMS Immunol Med Microbiol. 2007; 51: 535-546.
46. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem. 2002; 277: 50959-50965.
47. Konstantinov SR, Smidt H, de Vos WM. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc Natl Acad Sci U S A. 2008; 105: 19474-19479.
48. Ouwehand AC, Tiihonen K, Saarinen M, et al. Influence of a combination of Lactobacillus acidophilus NCFM and lactitol on healthy elderly: intestinal and immune parameters. Br J Nutr. 2009; 101: 367-375.
49. Shadnoush M, Shaker Hosseini R, Mehrabi Y. Probiotic yogurt affects pro-and anti-inflammatory factors in patients with inflammatory bowel disease. Iran J Pharm Res. 2013; 12: 929-936.
50. Tanriover MD, Aksoy DY, Unal S. Use of probiotics in various diseases: evidence and promises. Pol Arch Med Wewn. 2012; 122 Suppl 1: 72-77.